Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth. | Image Credit: phimprapha - stock.adobe.com
Over the past 10 years, the biologics market has demonstrated significant savings of $36 billion, along with increased patient access and a stronger supply chain, according to Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health and a member of The Center for Biosimilars® Advisory Board.
Speaking at the 2025 Festival of Biologics USA, taking place April 23-24 in San Diego, California, Poore highlighted a Cardinal Health report reviewing the past decade's biosimilar milestones.
The biosimilars market has increased patient access, particularly for costly treatments, and established a stronger overall supply chain. Furthermore, biosimilars foster a competitive landscape that curbs price escalation, and regulatory maturation alongside stakeholder education and acceptance have shifted approval processes while increasing trust in biosimilars.
“I remember when we first launched the biosimilars, I was in the industry then as well, and we were just trying to teach about how they got to market, the approval process. We don't have to talk about that so much anymore. Now we're talking about sustainability. We're talking about viability. We've evolved. We've matured,” Poore explained.
Education has moved the industry, but continued efforts are necessary for growth as more biosimilars enter new therapeutic areas. Poore referred to research focused on the retina, a biosimilar market with fast uptake, where ranibizumab biosimilars have reached 55% uptake. Poore emphasized that the future of retina biosimilars is promising, with the aflibercept market estimated to have $6.3 billion in wholesale acquisition cost sales in 2024.
“Dr [Jon] Adelberg, one of the retina specialists I spent a lot of time with, said that in his practice, only 1 in every 100 patients knows what a biosimilar is. If you think that the education piece is over, it's not,” Poore said.
In oncology, practices have found ways to make biosimilars more profitable, thus improving adoption despite economic barriers like reimbursement policies and pricing dynamics and noneconomic barriers such as provider/patient awareness, inventory management, and benefit investigation processes.
Poore emphasized that tight revenue cycle management, strong collaboration with a pharmacy team, payer analysis, and on-time ordering are some avenues for success. She also addressed sustainability concerns, noting adalimumab biosimilars have a 28% market share, falling short of the predicted 46% by the end of 2025, despite the demonstrated cost savings potential of biosimilars.
Poore explained how the oncology biosimilars market aligns with the value-based care model to improve patient outcomes and reduce costs, and practices with strong payer relationships can successfully leverage them to secure biosimilar coverage.
Looking ahead, Poore highlighted key priorities:
Poore expressed concerns about whether the current drug pipeline is sufficient to provide market savings for funding future innovations, align stakeholder incentives, and ensure market viability and profitability.
“I do believe the foundation has been built, and I think we've done a great job the last decade of building the foundation. Obviously, we have not unleashed the full impact of this market, but we have the next 10 years to do that,” Poore concluded.
Reference
Poore D. A decade of biosimilars. Presented at: Festival of Biologics USA; April 23-24, 2025; San Diego, CA.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD
March 18th 2025Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.